Introduction {#sec1}
============

Concomitant chemoradiation is used as an organ-sparing treatment strategy for advanced oropharyngeal and larynx cancers. Although outcomes vary based on stage, site, and other factors including human papilloma virus status, the 3-year progression-free survival of patients with advanced-stage head and neck cancer after chemoradiation therapy (CRT) is ∼60% ([@B1]). Patients in whom cancer recurs after initial CRT are considered for salvage surgery; but, patients with presalvage Stage IV disease and those with presalvage Stage III disease at recurrence have poor prognosis with a median survival of \<6 month and 14 months, respectively ([@B2]). As both new targeted therapies and radiation therapy (RT) delivery methods are developed, there is a need to develop biomarkers that may help stratify patients *a priori* for different treatment modalities or that can predict the likelihood of durable response versus ultimate failure earlier during therapy to allow for adaptive treatment approaches.

Positron emission tomography (PET) with ^18^F-fluorodeoxyglucose (FDG PET) is widely used in pretreatment staging and post-therapy evaluation of head and neck cancers after RT or CRT. Because of its high negative predictive value in detection of recurrent disease, the National Comprehensive Cancer Network Guidelines now recommend omitting consolidative surgery (neck dissection) if the post-therapy FDG PET obtained at least 12 weeks after initial therapy is negative for residual tumor ([@B3]). However, the role of FDG PET in predicting failure of CRT or monitoring treatment response to (chemo)radiation during or early after treatment is not well established (12 weeks after initial therapy is typically required).

Radiation therapy and chemotherapy affect proliferation rates in treated tumors. In addition, pretreatment proliferation rates may be a determinant of sensitivity to chemotherapy and RT. Assessment of cancer proliferation rates and changes in cell proliferation rate may therefore accurately predict ultimate therapeutic response. 3′-deoxy-3′-^18^F-fluorothymidine (FLT), a thymidine analogue that is not incorporated into DNA, is the most widely studied PET agent for imaging cell proliferation. The intracellular trapping of FLT is regulated by thymidine kinase 1, a key enzyme in DNA synthesis, with high activity during the proliferative phase of the cell cycle and low activity in the quiescent phase ([@B4]). Several studies have shown that untreated head and neck cancers can be imaged with FLT PET with a high tumor-to-background contrast ([@B5]--[@B9]).

Radiomics is an image analysis approach with the goal of extracting large amounts of quantitative information from medical images using a variety of computational methods. Extracted features include measurements of intensity (uptake), shape, and texture. The objective of this study was to evaluate the utility of FLT PET radiomic features obtained at baseline in the prediction of treatment response in patients with head and neck squamous cell cancer (HNSCC). The present work provides a basis for further optimization of predictive FLT PET features, which can then be further evaluated in future clinical trials.

Methodology {#sec2}
===========

Patients {#sec2-1}
--------

A single-center prospective study was performed in patients who had histologically confirmed HNSCC and were scheduled to receive definitive concurrent CRT per standard cancer care. Other eligibility criteria included a Karnofsky score of ≥60, acceptable bone marrow reserve (absolute neutrophil count, ≥1.5 K/mL; platelet count, ≥100 K/mL) and kidney (serum creatinine, ≤2.1 mg/dL), and liver function (bilirubin, ≤1.0 mg/dL; ALT/AST, ≤2.5 times upper limits of normal for the institution). These criteria generally excluded patients who were not robust enough to receive combined modality therapy. Patients were excluded if they had chemotherapy or radiotherapy within 4 weeks before the study (no induction chemotherapy) or were receiving investigational drugs or nucleoside analogues (such as 5-Fluorouracil that could interfere with FLT uptake). All patients were scheduled to undergo a baseline FLT PET scan within 30 days of the initiation of CRT. This was generally done the week before starting treatment. Platinum-based chemotherapy was started the first day of radiotherapy, either with high-dose cisplatinum or a combination of cisplatinum or carboplatinum combined with a taxane. Patients were followed every 3 months with clinical exams for the first year per our clinical routine and 2--4 times per year subsequently. Surveillance FDG PET scans were obtained at 3--4 months after treatment. Subsequent follow-up imaging was individualized on the basis of symptoms and clinical findings. This research was approved by the University of Iowa Institutional Review Board, and all subjects signed an informed consent. The research was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice.

In total, 30 patients with squamous cell head and neck cancer, including 27 oropharyngeal cancers, 1 unknown primary, and 2 laryngeal cancers, were available for analysis. There were 26 male and 4 female patients with an age range of 36--76 years (median, 57 years). The demographics of the patients including distribution of tumor stages are summarized in [Table 1](#T1){ref-type="table"}. After a median follow-up of 26 months (range, 7--36 months), 8 patients died of disease, 1 patient was alive with distant metastasis (DM), and 21 patients had no evidence of disease. Among the 8 patients who died from the disease, 4 patients had local recurrence (LR), 1 patient had local recurrence and distant metastasis (LR + DM), and 3 patients had DM alone at the time of initial recurrence or progression. Three patients underwent salvage surgery after completion of radiotherapy because of local recurrence and had no evidence of disease at last follow-up. The median follow-up in patients with no evidence of disease was 25 months.

###### 

Overview of Patients in the FLT PET Study (*n* = 30)

  Patient Characteristics    Categories                  Total \[%\]                                 Median \[Range\]
  -------------------------- --------------------------- ------------------------------------------- --------------------
  Age at diagnosis (years)                                                                           57 \[36--76\]
  Sex                        Male                        26 \[86.7\]                                 
                             Female                      4 \[13.3\]                                  
  Site                       Oropharynx                  27 \[90.0\]                                 
                             Larynx                      2 \[6.7\]                                   
                             Unknown primary             1 \[3.3\]                                   
  T-Stage                    Tx                          1 \[3.3\]                                   
                             T1                          1 \[3.3\]                                   
                             T2                          15 \[50.0\]                                 
                             T3                          7 \[23.3\]                                  
                             T4                          6 \[20.0\]                                  
  N-Stage                    N0                          5 \[16.7\]                                  
                             N1                          5 \[16.7\]                                  
                             N2                          16 \[53.3\]                                 
                             N3                          4 \[13.3\]                                  
  Overall Stage              II                          2 \[6.7\]                                   
                             III                         9 \[30.0\]                                  
                             IVA                         13 \[43.3\]                                 
                             IVB                         6 \[20.0\]                                  
  Follow-Up (Months)                                                                                 22.0 \[4.6--36.0\]
  Survival Status            Progression-free survival   21 \[70\]                                   
                             Progression or death        9^[a](#TF1-1){ref-type="table-fn"}^\[30\]   

^a^ Consists of 4 patients with LR, 4 patients with DM, and 1 patient with LR + DM.

FLT PET Imaging {#sec2-2}
---------------

For the synthesis of FLT, fluorine-18 fluoride was reacted with 3′-anhydrothymidine-5′-benzoate following the procedure of Machulla et al. ([@B10]). The benzoate protecting group was removed with base hydrolysis and the product purified by semiprep HPLC with 10% ethanol/90% isotonic saline as the mobile phase with typical yields of 5%--8%. FLT was infused via a syringe pump over 2 minutes followed by 10-mL saline flush administered manually. The administered activity of FLT was 2.6 MBq/kg (0.07 mCi/kg) with a maximum dose of 185 MBq (5 mCi). Imaging was performed on a Siemens ECAT EXACT HR + PET scanner (Siemens Medical Solutions USA, Inc., Knoxville, TN) for 40 minutes, starting 60 minutes after injection. Transmission imaging was performed before the injection of FLT. Whole-body scans were obtained for 28 patients, and scans of the head and neck region were obtained for only 2 patients. Images were iteratively reconstructed (2 iterations = 8 subsets, Gaussian 8.0 mm, zoom = 1.2) with a resulting voxel size of 4.29 × 4.29 × 4.29 mm.

Image Analysis {#sec2-3}
--------------

For primary tumors and FLT-avid lymph nodes, volumes of interest (VOIs) defined by high FLT uptake above background were generated by a nuclear medicine physician using a semiautomated segmentation software developed for head and neck tumors in PET ([@B11]). Primary tumors were segmented on FLT PET in all patients except for 1 patient who had an unknown primary tumor site. FLT-avid nodal metastases in the neck were identified in 23 patients. In total, 83 lesions/VOIs were identified using the semiautomated PET segmentation tool. Each VOI received an individual label. Subsequently, these labels were used to define 2 different measurement region categories (ie, VOIs) from which radiomic features were extracted. The first measurement region category PT consisted of VOIs representing primary tumor only. The second category LB was the total lesion burden, which corresponds to the primary tumor and all FLT-avid nodes combined. To calculate quantitative features for LB, all lesion previously segmented in a FLT scan were combined into 1 image mask, forming a single VOI. For each measurement region, radiomic features describing intensity, shape, and texture properties were calculated by using the open-source packages PET-IndiC ([@B12]) and pyradiomics ([@B13]). All features were derived from standardized uptake value (SUV) normalized PET images. A total of 104 quantitative baseline PT features and an additional 99 baseline LB features were extracted from each patient. Note that 5 shape features (ie, slice maximum 2D diameter, column maximum 2D diameter, row maximum 2D diameter, maximum 3D diameter, and sphericity) are meant for single, connected VOIs, so these were excluded from the LB features.

For texture features, the histogram bin size was fixed at 0.25 SUV. The selected bin size follows van Velden et al. ([@B14]), where the total number of bins will be ∼64 bins, depending on the lesion SUV range. A fixed bin size is used rather than a fixed number of bins because lesion SUV ranges vary among patients and fixing the number of bins is less appropriate for the clinical setting ([@B15]).

In addition to SUV-based measurements, normalized measurements of uptake were calculated by dividing lesion SUVs by the mean SUV in the bone marrow. The goal of normalization is to compare the cell proliferation in cancerous tissue to that of a normal structure. Normalization of SUVs was accomplished by generating a VOI around the largest vertebra completely visible in the field of view using the same segmentation software described above. In total, 30 vertebral VOIs were created using the semiautomated segmentation tool. For most patients, the L5 vertebra was segmented. The L4 vertebra was segmented for 1 patient owing to the L5 vertebra not being completely within the field of view. Because 2 patients had PET scans that did not include lumbar vertebrae, the T4 or T6 vertebra were segmented instead. Patient SUVs were then normalized by dividing by the mean vertebral SUV, and radiomic features were again calculated from the lesion VOIs. In total, 87 vertebra-normalized PT features and 87 vertebra-normalized LB features were generated from each patient. Note that normalization is not applicable for 11 features (ie, shape features) and has no effect on Q1--Q4 distributions, skewness, and kurtosis. For texture features based on normalized uptake, the histogram bin size was fixed at 0.125 (unitless). Note that the bin size is reduced compared with unnormalized texture features (bin size, 0.25), because normalization reduces the lesion intensity ranges compared with unnormalized lesions. In total, 377 baseline radiomic features were extracted from each patient.

Feature Reduction {#sec2-4}
-----------------

Redundancy of quantitative features was reduced by using a clustering algorithm. The goal of feature reduction was to replace highly correlated features with a single representative feature. Such a step could be achieved by utilizing a PCA-based feature selection step \[eg, FactoMineR ([@B16])\]. However, due to the sparseness of our feature space, a more appropriate feature selection method was utilized. First, the similarities of features were calculated by determining the Pearson correlation (*r*) for all pairs of features. Next, features were clustered according to similarity using an affinity propagation (AP) clustering algorithm ([@B17]), an unsupervised dimension reduction technique that others have utilized in the analysis of quantitative imaging features ([@B18]--[@B20]). An advantage of AP clustering over *k*-means clustering is that the total number of clusters at the output is automatically determined. Moreover, the algorithm is able to handle infinite dissimilarities, meaning 2 features that are highly dissimilar will not be placed in the same cluster. Therefore, to allow features with only strong correlations defined by *r* ≥ 0.90 to be clustered together, all features with pairwise similarity values less than 0.90 were artificially set to have infinite dissimilarity before application of the AP clustering algorithm. As output, the algorithm produces a reduced set of representative exemplar features. An exemplar feature can be either a single feature with no strong correlations with other features or a representative of a cluster containing ≥2 features. The feature reduction step was performed using the *apcluster* package ([@B21]) in version 3.2.3 of the R statistical software ([@B22]).

Statistical Evaluation {#sec2-5}
----------------------

Survival analysis was conducted to estimate and test the effects of quantitative features in the reduced set on progression-free survival (PFS). Time to event for PFS was defined as time from start of treatment to recurrence or death. Effects on survival during the 36-mo, post-treatment period were of primary interest. Hence, subjects who did not experience an event by month 36 were censored at that point in time for the analysis. Cox regression was used to model the effects of individual quantitative features on survival. Using multiple predictors in a Cox regression model on a small cohort has the potential to overfit the patient data. Therefore, a Cox model with a single predictor was chosen to avoid overfitting. Estimated effects are summarized with hazard ratios (HRs) and the concordance (*c*)-index. The *c*-index is an estimate of the probability that, out of 2 randomly selected patients, the model can discriminate which patient will survive longer ([@B23]). Values can range from 0.0 to 1.0, with 0.5 indicating absence of discriminant value for the model, 0.7 indicating reasonable discriminant value, and 1.0 indicating perfect discriminant value. Two-sided *P*-values for tests of significance of features in the models are reported. To account for multiple statistical tests, the false-discovery rate (FDR) was computed using the Benjamini--Hochberg method ([@B24]). Features with a FDR of 10% were identified as significant. All statistical tests were performed using the *survival* package ([@B25]) for R.

Interobserver Variability Analysis {#sec2-6}
----------------------------------

To study the variabiltity of feature measurement, a second observer independently generated segmentations (VOIs) for the same 83 lesions and features were calculated as described above. The features extracted from the second observer\'s VOIs were then compared to the features extracted from the VOIs of the first observer. Agreement in feature measurement was compared using the intraclass correlation coefficient (ICC). To investigate the impact of interobserver segmentations on model performance, a separate model for each predictive feature was generated using segmentations by the second observer. The performance of these models were then compared to the initial models from the first observer. Differences of model performance were reported as changes in *c*-index values.

Results {#sec3}
=======

Feature Reduction {#sec3-1}
-----------------

The feature reduction step took the 377 FLT features as input and clustered similar features together to produce 172 uncorrelated clusters. [Figure 1](#F1){ref-type="fig"} shows the distribution of cluster sizes. Ninety-six clusters had a size of one, meaning there were 96 features (25.5%) that were not highly correlated with any other feature (*r* \< 0.9). The remaining 76 clusters had size of ≥2, with the maximum being a size of 10.

![Cluster size distribution for the 172 clusters identified in the feature reduction step.](tom0011901450001){#F1}

Correlation of Baseline Features With Treatment Outcome {#sec3-2}
-------------------------------------------------------

Feature performance was estimated using each feature as a predictor in a univariate Cox regression model. A total of 37 exemplar baseline features (21.5%) had *P*-values below the 5% level. After adjusting for multiple testing to control the false-discovery rate, a total of 9 baseline features were identified as significant at the set 10% FDR level. [Table 2](#T2){ref-type="table"} summarizes the unadjusted Cox regression *P*-values, estimated hazard ratios with corresponding confidence intervals, FDRs, and *c*-index values for the 9 significant features as well as for 3 commonly used features (ie, SUV~*max*~, SUV~*peak*~, and SUV~*mean*~). SUV~*peak*~ was defined as the highest average uptake within a 1 cm^3^ sphere that is completely contained within the VOI. Note that SUV~*peak*~ and SUV~*mean*~ were not selected in the feature reduction step, so univariate analyses were done separately and no FDRs were calculated for SUV~*peak*~ and SUV~*mean*~. The clinical parameter for primary tumor stage (T-stage) was not significantly associated with survival.

###### 

Comparison of Predictive FLT Features (Progression-Free Survival) With 3 Commonly Used Features, SUV~*max*~, SUV~*peak*~, and SUV~*mean*~

  Feature (VOI, normalization)                                                     *P*-Value   HR \[95% CI\]          FDR     *c*-Index
  -------------------------------------------------------------------------------- ----------- ---------------------- ------- -----------
  Gray-Level Non-Uniformity^[a](#TF2-1){ref-type="table-fn"}^ (LB, N)              0.0002      3.11 \[1.70, 5.68\]    0.043   0.86
  Gray-Level Non-Uniformity^[b](#TF2-2){ref-type="table-fn"}^ (LB, N)              0.0012      3.12 \[1.56, 6.24\]    0.058   0.72
  Spherical Disproportion (LB, U)                                                  0.0012      4.10 \[1.56, 10.80\]   0.058   0.74
  Information Measure of Correlation 2^[c](#TF2-3){ref-type="table-fn"}^ (LB, U)   0.0017      0.32 \[0.16, 0.65\]    0.058   0.79
  Zone Percentage^[b](#TF2-2){ref-type="table-fn"}^ (LB, N)                        0.0020      0.18 \[0.04, 0.78\]    0.058   0.75
  Gray-Level Non-Uniformity^[a](#TF2-1){ref-type="table-fn"}^ (LB, U)              0.0020      2.21 \[1.40, 3.47\]    0.058   0.83
  Q1 Distribution (LB, U)                                                          0.0042      0.36 \[0.17, 0.75\]    0.088   0.78
  Volume (LB, U)                                                                   0.0043      2.44 \[1.38, 4.32\]    0.088   0.74
  Information Measure of Correlation 1^[c](#TF2-3){ref-type="table-fn"}^ (LB, U)   0.0046      4.07 \[1.23, 13.42\]   0.088   0.78
  SUV~*max*~ (LB, U)                                                               0.1916      0.60 \[0.27, 1.33\]    0.395   0.66
  SUV~*peak*~^[d](#TF2-4){ref-type="table-fn"}^ (LB, U)                            0.3341      0.69 \[0.32, 1.48\]    ---     0.63
  SUV~*mean*~^[d](#TF2-4){ref-type="table-fn"}^ (LB, U)                            0.5038      0.76 \[0.34, 1.71\]    ---     0.62

Abbreviations: VOI, volume of interest; HR, hazard ratio; CI, confidence interval; FDR, false-discovery rate; PT, primary tumor; LB, lesion burden; U, unnormalized; N, normalized.

^a^ Calculated from the gray-level run length matrix (GLRLM).

^b^ Calculated from the gray-level size zone matrix (GLSZM).

^c^ Calculated from the gray-level co-occurrence matrix (GLCM).

^d^ Not selected in feature reduction step, so FDR was not calculated.

[Figure 2](#F2){ref-type="fig"} shows a heatmap of correlations among the 9 significant features. The feature reduction step used a high correlation threshold (*r* ≥ 0.90), so moderate correlations among the best-performing features still exist. By showing the correlations of the features in a heatmap, good-performing lesion characteristics, rather than individual features, may be observed. For example, features that measure lesion size (eg, volume) and shape (eg, spherical disproportion) had good performance. Also, measures of lesion heterogeneity (eg, gray-level nonuniformity and zone percentage) had good performance.

![Heatmap of correlations among the 9 baseline ^18^F-fluorothymidine (FLT) features with the best performance.](tom0011901450002){#F2}

Interobserver Variability Analysis {#sec3-3}
----------------------------------

[Table 3](#T3){ref-type="table"} shows the results of the variability analysis for the 9 significant features and the commonly used features SUV~*max*~, SUV~*peak*~, and SUV~*mean*~. Gray-level nonuniformity from the gray-level size zone matrix (GLSZM) had moderate agreement between the 2 observers. The other 8 significant features had strong agreement between the 2 observers. Both SUV~*max*~ and SUV~*peak*~ had perfect agreement between the 2 observers and SUV~*mean*~ had strong agreement.

###### 

Interobserver Agreement for Predictive FLT Features and 3 Commonly Used Features, SUV~*max*~, SUV~*peak*~, and SUV~*mean*~

  Feature (VOI, normalization)                                                     Measurement Agreement
  -------------------------------------------------------------------------------- -----------------------
  Gray-level Non-Uniformity^[a](#TF3-1){ref-type="table-fn"}^ (LB, N)              0.99
  Gray-level Non-Uniformity^[b](#TF3-2){ref-type="table-fn"}^ (LB, N)              0.75
  Spherical Disproportion (LB, U)                                                  0.96
  Information Measure of Correlation 2^[c](#TF3-3){ref-type="table-fn"}^ (LB, U)   0.98
  Zone Percentage^[b](#TF3-2){ref-type="table-fn"}^ (LB, N)                        0.91
  Gray-level Non-Uniformity^[a](#TF3-1){ref-type="table-fn"}^ (LB, U)              0.99
  Q1 Distribution (LB, U)                                                          0.90
  Volume (LB, U)                                                                   0.99
  Information Measure of Correlation 1^[c](#TF3-3){ref-type="table-fn"}^ (LB, U)   0.95
  SUV~*max*~ (LB, U)                                                               1.00
  SUV~*peak*~ (LB, U)                                                              1.00
  SUV~*mean*~ (LB, U)                                                              0.94

Measurement agreement was calculated as the Intraclass Correlation Coefficient (ICC) between the feature values of the first and second observer.

Abbreviations: VOI, volume of interest; LB, lesion burden; U, unnormalized; N, normalized.

^a^ Calculated from the gray-level run length matrix (GLRLM).

^b^ Calculated from the gray-level size zone matrix (GLSZM).

^c^ Calculated from the gray-level co-occurrence matrix (GLCM).

To assess model performance stability, the segmentations of the second observer were used to produce a second model for each of the predictive features shown in [Table 2](#T2){ref-type="table"}. [Table 4](#T4){ref-type="table"} shows the performance differences of the second model in reference to the first model for the univariate predictors with the best performance. For most features, only small changes in performance (*c*-index) were observed, indicating that model performance was stable. Only 1 feature (Q1 distribution) had a change in *c*-index \>5 percentage points.

###### 

Differences of Model Performance Due to Interobserver Segmentation Variability

  Feature (VOI, normalization)                                                     Δ*c*-index
  -------------------------------------------------------------------------------- ------------
  Gray-Level Non-Uniformity^[a](#TF4-1){ref-type="table-fn"}^ (LB, N)              0.00
  Gray-Level Non-Uniformity^[b](#TF4-2){ref-type="table-fn"}^ (LB, N)              −0.01
  Spherical Disproportion (LB, U)                                                  −0.03
  Information Measure of Correlation 2^[c](#TF4-3){ref-type="table-fn"}^ (LB, U)   0.03
  Zone Percentage^[b](#TF4-2){ref-type="table-fn"}^ (LB, N)                        0.01
  Gray-Level Non-Uniformity^[a](#TF4-1){ref-type="table-fn"}^ (LB, U)              0.01
  Q1 Distribution (LB, U)                                                          −0.07
  Volume (LB, U)                                                                   −0.01
  Information Measure of Correlation 1^[c](#TF4-3){ref-type="table-fn"}^ (LB, U)   0.03

Change Calculations are the Difference (Δ) of the *c*-Indices Between the Model of the First Observer and the Model of the Second Observer.

Abbreviations: VOI, volume of interest; LB, lesion burden; U, unnormalized; N, normalized.

^a^ Calculated from the gray-level run length matrix (GLRLM).

^b^ Calculated from the gray-level size zone matrix (GLSZM).

^c^ Calculated from the gray-level co-occurrence matrix (GLCM).

Discussion {#sec4}
==========

Performance {#sec4-1}
-----------

In this work, we investigated associations of patient outcomes with radiomic features derived from FLT PET lesion segmentations. Radiomics generates many features that can be highly correlated from each subject, so a feature reduction step was included to remove redundancies from the feature space. Despite this reduction, a large number of features were not highly correlated and tested in the performance analysis, so controlling the false-discovery rate was used to reduce false positives. A total of 9 FLT features were considered significant.

Our results suggest that a favorable prognosis is associated with a small lesion size, a more sphere-like lesion shape, and homogeneous intensity. [Figure 3](#F3){ref-type="fig"} shows the baseline scans of 2 patients with different outcomes and different FLT-avid lesion shapes. The surviving patient ([Figure 3A](#F3){ref-type="fig"}) has a small, sphere-like lesion. The patient later classified with progressive disease ([Figure 3B](#F3){ref-type="fig"}) has large lesions with a large, irregular surface area. Our results also suggest that lesion texture/homogeneity of intensity may be an indicator of outcome. [Figure 4](#F4){ref-type="fig"} shows the baseline scans of 2 patients with different outcomes and different lesion textures. The surviving patient ([Figure 4A](#F4){ref-type="fig"}) has lesions with smaller regions of more uniform texture. The patient later classified with progressive disease ([Figure 4B](#F4){ref-type="fig"}) has large regions and an overall nonuniform texture.

![Baseline FLT scan slices showing differences in lesion size and shape. Patient later classified as progression-free survival at follow-up (A). Patient later classified as progression at follow-up (B). A favorable prognosis was associated with small tumor volume (Vol) and a lower spherical disproportion (SphDisp).](tom0011901450003){#F3}

![Baseline FLT scan slices showing differences in lesion texture. Patient later classified as progression-free survival at follow-up (A). Patient later classified as progression at follow-up (B). A favorable prognosis was associated with more homogeneous lesions and finer textures. Gray-level nonuniformity from the gray-level run length matrix (GLNU) has a lower value for more uniform regions. Zone percentage from the gray-level size zone matrix (ZonePct) has a higher value for regions with finer textures.](tom0011901450004){#F4}

The authors are not aware of any publications that normalize lesion uptakes with the mean vertebral uptake before analysis of response prediction for HNSCC with FLT PET. Three out of the 5 best-performing intensity-based features were normalized with the mean vertebral uptake. [Table 5](#T5){ref-type="table"} compares the *c*-indices of intensity-based FLT features with and without normalization. Texture features from the gray-level co-occurrence matrix have poorer performance after normalization. Texture features from the gray-level run length matrix and the GLSZM have a small increase in performance after normalization. Due to our small cohort of patients, more analysis is needed on a larger patient population to determine if these differences are significant.

###### 

Comparison of *c*-Index Values for Unnormalized and Normalized Features

  Feature                                                                  Unnormalized   Normalized
  ------------------------------------------------------------------------ -------------- ------------
  Gray-Level Non-Uniformity^[a](#TF5-1){ref-type="table-fn"}^              0.83           **0.86**
  Gray-Level Non-Uniformity^[b](#TF5-2){ref-type="table-fn"}^              0.66           **0.72**
  Information Measure of Correlation 2^[c](#TF5-3){ref-type="table-fn"}^   **0.79**       0.63
  Zone Percentage^[b](#TF5-2){ref-type="table-fn"}^                        0.73           **0.75**
  Information Measure of Correlation 1^[c](#TF5-3){ref-type="table-fn"}^   **0.78**       0.56

Higher c-Index Values for Each Feature are Indicated in Bold.

^a^ Calculated from the gray-level run length matrix (GLRLM).

^b^ Calculated from the gray-level size zone matrix (GLSZM).

^c^ Calculated from the gray-level co-occurrence matrix (GLCM).

All features identified as having an association with patient outcome were calculated from the total lesion burden ([Table 2](#T2){ref-type="table"}). This suggests that important information about the disease is found not only in the primary tumor, but also in the FLT-avid lymph nodes. [Table 6](#T6){ref-type="table"} compares the *c*-indices of the 9 best-performing FLT features calculated from the primary tumor and the total lesion burden. All but 1 feature (ie, information measure of correlation 1) had higher performance when calculated from the total lesion burden. Furthermore, the interoperator agreement (ICC) average and standard deviation of the 9 best-performing FLT features for primary tumor and the total lesion burden was 0.88 ± 0.13 and 0.94 ± 0.08, respectively. Thus, FLT PET features derived from total lesion burden show higher agreement, and 8 out of the 9 best-performing features had strong agreement between different observers ([Table 3](#T3){ref-type="table"}). As stated before, more analysis is needed on a larger patient population to determine if these differences are significant.

###### 

Comparison of *c*-Index Values for Features Calculated from the Primary Tumor and the Total Lesion Burden

  Feature (Normalization)                                                      Primary Tumor   Lesion Burden
  ---------------------------------------------------------------------------- --------------- ---------------
  Gray-Level Non-Uniformity^[a](#TF6-1){ref-type="table-fn"}^ (N)              0.71            **0.86**
  Gray-Level Non-Uniformity^[b](#TF6-2){ref-type="table-fn"}^ (N)              0.50            **0.72**
  Spherical Disproportion (U)                                                  0.49            **0.74**
  Information Measure of Correlation 2^[c](#TF6-3){ref-type="table-fn"}^ (U)   0.75            **0.79**
  Zone Percentage^[b](#TF6-2){ref-type="table-fn"}^ (N)                        0.68            **0.75**
  Gray-Level Non-Uniformity^[a](#TF6-1){ref-type="table-fn"}^ (U)              0.71            **0.83**
  Q1 Distribution (U)                                                          0.64            **0.78**
  Volume (U)                                                                   0.59            **0.74**
  Information Measure of Correlation 1^[c](#TF6-3){ref-type="table-fn"}^ (U)   **0.79**        0.78

Higher *c*-Index Values for Each Feature are Indicated in Bold.

Abbreviations: U, unnormalized; N, normalized.

^a^ Calculated from the gray-level run length matrix (GLRLM).

^b^ Calculated from the gray-level size zone matrix (GLSZM).

^c^ Calculated from the gray-level co-occurrence matrix (GLCM).

Related Work {#sec4-2}
------------

The association of standard FLT features and outcome has been previously studied. For example, Hoshikawa et al. reported that baseline FLT tumor volume and total lesion proliferation (TLP) were predictive of locoregional tumor control in 32 patients with HNSCC treated with CRT and surgery ([@B26]). We found similar results to their findings for the total lesion burden volume (*P* = .004) and total lesion burden TLP (*P* = .012) for predicting 3-y progression-free survival. Note that total lesion burden TLP in our analysis was not selected during the feature reduction step. Hoshikawa et al. later reported that baseline FLT tumor volume, TLP, and SUV~*max*~ were predictive of locoregional tumor control in 53 patients with HNSCC treated with RT or CRT ([@B27]). Our results are not similar to their findings for unnormalized SUV~*max*~ (*P* = .192). This may be due to our smaller patient cohort (30 vs. 53). However, Linecker et al. reported earlier that high FLT uptake is associated with poor outcome in 20 patients treated with RT and CRT ([@B8]).

The authors are aware of 2 other publications that report correlations of FLT based radiomic features and patient outcomes. Willaime et al. reported that radiomic features were predictive of treatment response in 11 breast cancer patients treated with chemotherapy ([@B28]). However, the different cancer site and treatment type does not allow for a meaningful comparison with our results. Majdoub et al. ([@B29]) reported that tumor proliferative volume and textural features are predictive of disease-free survival in 45 patients with HNSCC treated with RT and CRT. They found that large, more heterogeneous lesions were associated with a less favorable prognosis, which is consistent with our findings.

In current clinical practice, FDG PET imaging is commonly utilized for assessment of response to treatment. For this purpose, simple quantitative image features like SUVmax, SUVpeak ([@B30]), metabolic tumor volume (MTV), or total lesion glycolysis (TLG) have been proposed, out of which SUVmax is most widely adopted. In a recent study, Castelli et al. ([@B31]) summarized the results of 45 studies regarding the predictive value of such FDG PET features with respect to clinical outcome in HNC treatment with chemoradiotherapy (CRT). The study concluded that MTV and TLG in pretreatment PET scans showed good correlation with disease free survival (DFS) or overall survival (OS). In this work, we have investigated FLT PET derived image features. At this stage, it is unclear which imaging approach (ie, tracer) results in better predictive performance. For example, the volume defined by above normal tracer uptake showed good performance on FLT data ([Table 2](#T2){ref-type="table"}) as well as in FDG PET studies ([@B31]). However, to decide which approach is preferable, a dedicated study is needed.

Limitations {#sec4-3}
-----------

This study has several limitations. The HPV (human papilloma virus) status, which is now a well-known prognostic factor in oropharyngeal cancers, was not available for this cohort as it was not routinely obtained when subjects were enrolled in this study. Furthermore, the effects of repeated scans and image reconstruction parameters on FLT-based radiomic features was not determined. Willaime et al. did investigate test--retest variability of texture features in breast cancer using FLT PET ([@B28]). They report similar results to a study by Tixier et al., which investigated the test-retest variability of FDG PET texture features using 16 patients with esophageal cancer ([@B32]). Both studies found that measures of tumor homogeneity and entropy had good repeatability. Leijenaar et al. investigated the repeatability of FDG PET texture features in non--small cell lung cancer ([@B33]). A majority of features (71%) were stable during test-retest analysis.

Yan et al. reported that zone percentage of the GLSZM was sensitive to image reconstruction parameters and should be used with caution ([@B34]). Their work used 20 patients with lung lesions imaged with FDG PET. Zone percentage was associated with patient outcome in our results, and it is a measure of fine textures. It is reasonable to expect that high variability of zone percentage calculations by different image reconstruction parameters would also occur in FLT PET. Reconstruction parameters were held constant for the images in our study.

Conclusion {#sec5}
==========

In conclusion, radiomics is a useful approach for extracting large amounts of information from tumor images. We investigated the association of patient outcomes with radiomic features extracted from tumors imaged with FLT PET. Radiomics features performed favorably compared to standard clinical stage. We found that smaller, more homogenous lesions at baseline were associated with a better prognosis in 30 patients with head and neck cancer. Therefore, for future studies of FLT-based prediction of outcome, we recommend including radiomic features of lesion size, shape, and texture features that measure lesion homogeneity. We also recommend that radiomic features be calculated from the total lesion burden, rather than the primary tumor only, so that the largest amount of disease information is used for analysis. Our findings enable future optimization of FLT-based features which can then be assessed in validation studies.

Abbreviations: FLT^18^F-fluorothymidinePETpositron emission tomographyCRTchemoradiation therapyRTradiation therapyHNSCChead and neck squamous cell cancerDMdistant metastasisLRlocal recurrenceVOIsvolumes of interestGLSZMgray-level size zone matrixSUVstandardized uptake valueMTVmetabolic tumor volumeTLGtotal lesion glycolysis
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